Panic! No, don't panic! ECJ embryonic stem cells ruling divides opinion
This article was originally published in Scrip
One set of interested parties has loudly bemoaned the European Court of Justice's ruling that embryonic stem cells cannot be patented, lamenting that it will stifle investment in research in the sector and lead to a shift in commercial development away from Europe. But another section of Europe's stem cell community has warned against such a reaction, arguing that paradoxically, the ruling could actually prove a net positive for the sector.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.